News | Mutabilis

CARB-X is funding French biotech MUTABILIS to develop a new class of antibacterials to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria

By: admutabilis | Tags: | Comments: 0

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.

Mutabilis presents EBL-1463 at the 2020 online AMR Conference.

By: admutabilis | Tags: | Comments: 0

September 2020. Due to the Covid-19 restrictions the 2020 AMR conference had to be held on the Internet this year. Within the session dedicated to the presentation of the IMI-ENABLE’s results, François Moreau, Mutabilis’ CSO, gave a presentation on EBL-1463. The presentation can be viewed here.

Novo Holdings REPAIR invests in Mutabilis

By: admutabilis | Tags: | Comments: 0

January 6th 2020: Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis to accelerate its 2G Dabocins program

Mutabilis will present at “Superbugs & Superdrugs”. 30-31 March 2020. London, UK.

By: admutabilis | Tags: | Comments: 0

Title of the talk : DISCOVERY OF DABOCINS, A NOVEL CLASS OF NON-BETA-LACTAM PBP INHIBITORS

ENABLE (IMI) selects one of Mutabilis’ programme as new antibiotic candidate. Nov 6th 2019

By: admutabilis | Tags: | Comments: 0

Following the integration of Mutabilis’ second programme in ENABLE in April 2018, the ENABLE Portfolio Management Committee has selected a candidate from this programme.

Mutabilis at the next ASM MICROBE conference held in San-Francisco from June 20th to 24th 2019

By: admutabilis | Tags: | Comments: 0

Mutabilis will be represented at the ASM MICROBE 2019 conference in San-Francisco from June 20th to 24th 2019.

Mutabilis at the 12th Berlin Conference on Novel Antimicrobials 2019

By: admutabilis | Tags: | Comments: 0

Like last year, Mutabilis delegates will participate to the Berlin Conference on Novel Antimicrobials and Diagnosstics 2019 on March 14th – 15th 2019.

The World Health Organization releases a report on the clinical pipeline of antibiotics

By: admutabilis | Tags: | Comments: 0

The World Health Organization had published earlier this year a list of the most concerning pathogens. The WHO continues with a report on the pipeline of antibiotics currently in clinical development to assess how we are going to manage the pathogens of the list.

Mutabilis joins the European ENABLE consortium to fight antibiotic resistance (october 17th 2017).

By: admutabilis | Tags: | Comments: 0

Mutabilis has been selected by the European ENABLE project (European Gram-negative Antibacterial Engine), which aims to improve the development of antibiotics against infections caused by multiresistant Gram-negative bacteria.

DRIVE-AB final conference : New economic models for much needed innovative antibiotics presented at the (5-6 september 2017, Brussels). (June 1st 2017)

By: admutabilis | Tags: | Comments: 0

The DRIVE-AB project is part of the IMI’s New Drug For Bad Bugs (ND4BB) initiative